Clinical Trial Update: Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating continuous once-daily oral afatinib (BIBW 2992) plus sirolimus (Rapamune) in patients with non-small cell lung cancer harboring EGFR mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• Rapamune (sirolimus)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED | Results posted: 2015-10-07